Безопасность и риск фармакотерапии (Oct 2024)

Postmarketing Surveillance: Review of Open Sources of Drug Safety Data

  • E. V. Shubnikova

DOI
https://doi.org/10.30895/2312-7821-2024-12-3-309-330
Journal volume & issue
Vol. 12, no. 3
pp. 309 – 330

Abstract

Read online

INTRODUCTION. Postmarketing surveillance is the main mechanism to monitor and evaluate the safety of drugs approved for widespread clinical use. This mechanism provides up-to-date information on adverse drug reactions and facilitates the implementation of necessary measures to prevent or minimize the risks associated with pharmacotherapy. Marketing authorization holders should regularly conduct searches for and analyses of drug safety data from all available sources. The lack of practical recommendations for selecting relevant information sources complicates the development of an optimal strategy for collecting drug safety data necessary for timely detection of changes in the safety profile of a drug that may affect the benefit–risk ratio.AIM. This study aimed to select the most appropriate methods for collecting drug safety information from the open sources used to monitor the safety profiles of approved drugs and assess their benefit–risk ratios.DISCUSSION. The main sources of new information on the safety of drugs include pharmacovigilance databases, websites of regulatory authorities, publications in medical scientific journals, and real-world clinical practice. According to the analysis results, the most widely used databases are the World Health Organization (WHO) VigiBase database, the European Union (EU) EudraVigilance database, and the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). This article also discusses the capabilities and interfaces of various applications for working with safety data, as well as the conditions for accessing databases. Additionally, the article provides detailed instructions on how to search for safety information on the websites of the European Medicines Agency (EMA) and FDA, which are considered to be the most reliable sources of information. Further, the article provides an overview of reputable medical journals most likely to publish articles on adverse drug reactions. In addition, the article covers bibliographic databases and search engines, which can simplify the search for scientific publications. Systematic monitoring of these sources can help marketing authorization holders to effectively assess the safety profiles and benefit–risk ratios of approved drugs.CONCLUSIONS. The use of recommended data sources can optimize the process of safety monitoring, significantly increase the identification rate for potential risks of pharmacotherapy, and facilitate the timely development of measures to prevent these risks. This, in turn, can contribute to improving the safety of patients and the quality of medical care.

Keywords